EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial

Khlood M Kettana, Sahar M El-Haggar, Mohamed A Alm El-Din, Dalia R El-Afify

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02426-1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Medical Oncology, 2024. Verfasst von Khlood M Kettana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. khlood.kettana@pharm.tanta.edu.eg. Hauptthemen laut MEDLINE: Breast Neoplasms, Rosuvastatin Calcium, Cardiotoxicity, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tanta University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiotoxicity is a side effect of chemotherapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients receiving both anthracyclines and trastuzumab. We looked for a possible protective effect of rosuvastatin against chemotherapy-induced cardiotoxicity. Methods: 50 newly diagnosed HER2 positive breast cancer patients were randomly allocated into two groups: 25patients in each. Group 1(control group) received doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy. Group 2 (treatment group) received doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin 24 h before the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months). Transthoracic echocardiography was done, and blood samples were collected for patients 24 h before the initiation of therapy, after 3 months and after 6 months to assess serum levels of high sensitivity cardiac troponin I (hs-cTnI), Myeloperoxidase (MPO), Interleukin-6 (IL-6) and Alanine aminotransferase (ALT). The study was retrospectively registered in Clinical Trials.gov in April 2022. Its ID is NCT05338723. Compared to control group, Rosuvastatin-treated group had a significantly lower decline in LVEF after 3 months and after 6 months. They had significantly lower Hs-cTnI and IL-6 after 3 months and after 6 months, and significantly lower MPO after 6 months. Four patients in control group experienced cardiotoxicity while no one in rosuvastatin-treated group. Rosuvastatin attenuated cardiotoxicity, so it is a promising protective agent against chemotherapy-induced cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRosuvastatin CalciumCardiotoxicityErb-b2 Receptor Tyrosine KinasesDoxorubicinTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultTroponin I

Stichwörter der Autor:innen

CardiotoxicityDoxorubicinRosuvastatinTrastuzumab

Substanzen

Rosuvastatin CalciumErb-b2 Receptor Tyrosine KinasesDoxorubicinTrastuzumabTroponin IERBB2 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. khlood.kettana@pharm.tanta.edu.eg.
  • Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Clinical Oncology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Förderung

  • Tanta University

Zitieren

APA

Kettana, K. M., El-Haggar, S. M., Alm El-Din, M. A., & El-Afify, D. R. (2024). Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. https://doi.org/10.1007/s12032-024-02426-1

Vancouver

Kettana KM, El-Haggar SM, Alm El-Din MA, El-Afify DR. Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. 2024. doi:10.1007/s12032-024-02426-1

BibTeX
@article{Kettana2024,
  author = {Kettana, Khlood M and El-Haggar, Sahar M and Alm El-Din, Mohamed A and El-Afify, Dalia R},
  title = {Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02426-1}
}
Kostenlos starten →